“Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program” (2022) SKIN The Journal of Cutaneous Medicine, 6(6), p. s48. doi:10.25251/skin.6.supp.48.